Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
One Medical, a chain of primary care clinics owned by Amazon, is being sued by the family of a man who died due to alleged provider negligence. Now, court filings reveal staff improperly accessed the deceased man's protected medical records.
Andrew Witty is stepping down as CEO of UnitedHealth Group, citing "personal reasons." Former CEO Stephen J. Hemsley has taken over, the company announced Tuesday.
A whistleblower lawsuit claims CVS pharmacies have overbilled state Medicaid programs for prescription drugs—a practice allegedly ongoing since 2016. The company denies any wrongdoing.
Pennant and BrightSpring Health Services have agreed to purchase some healthcare businesses from UnitedHealth and Amedisys. However, it remains unclear whether this will be enough for the DOJ to drop its lawsuit blocking the merger.
Deerfield Management released details on its latest Healthcare Innovations Fund program, promising to finance “promising therapeutics” and “elevating emerging technologies," including artificial intelligence.
In a lawsuit, plaintiffs allege the company changed course from a long-standing policy of denying medical claims, hiding from investors its impact on profits. The insurer denies any wrongdoing and vowed to defend itself in court.
If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.